SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

CRENESSITY

NBIX·NEUROCRINE BIOSCIENCES INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the U.S. since December 2024.
Why 4/10
CRENESSITY was FDA-approved on December 13, 2024, and is already generating significant commercial revenue. There is no pending PDUFA date, pivotal readout, or other hard binary catalyst scheduled in the next ~12 months. The drug's impact on NBIX shares will come through quarterly sales execution rather than a single binary event, so the impact score is capped at 4 per the rubric for approved drugs with no pending regulatory decision.
Actionable Insight NEUTRAL

CRENESSITY is already approved and generating strong sales growth ($211M in Q3 2026, annualizing above $800M). The next catalysts to watch are quarterly sales trajectory, potential European regulatory submission/approval, and any label expansion data readouts at medical conferences. With no binary PDUFA or pivotal readout ahead, the stock's near-term moves will be driven by commercial execution and INGREZZA/VYKAT XR performance rather than a single CRENESSITY catalyst.

Price Chart

Loading chart...

Executive Summary

CRENESSITY (crinecerfont) is a first-in-class oral CRF1 receptor antagonist approved by the FDA on December 13, 2024, for classic congenital adrenal hyperplasia (CAH) in adults and children aged 4 and older. Developed and marketed by Neurocrine Biosciences (NBIX), it is the first new treatment for CAH in 70 years, offering a steroid-sparing approach. The drug launched strongly, generating $301M in 2025 sales and accelerating to $211M in Q3 2026 alone (annualizing above $800M), with ~80% reimbursement rates and a rapidly expanding prescriber base. NBIX trades at $145 with a strong analyst consensus (32 Buy/Strong Buy, mean target $206, 41.9% implied upside). However, with no pending binary regulatory catalyst and the drug already in its commercial ramp phase, the near-term stock movement depends on quarterly execution rather than a single event.

How It Works

CRENESSITY (crinecerfont) is a pill that blocks a receptor in the pituitary gland called CRF1. In classic congenital adrenal hyperplasia (CAH), the body overproduces a hormone called ACTH, which in turn causes the adrenal glands to pump out excess androgen hormones (like testosterone). CRENESSITY interrupts this chain by blocking the signal that triggers ACTH release, thereby reducing androgen levels without needing to increase steroid doses. It is used alongside standard glucocorticoid (steroid) replacement therapy.

Trial Status

FDA approval was based on two Phase 3 randomized, double-blind, placebo-controlled trials (CAHtalyst program) in 182 adults and 103 children with classic CAH. Long-term open-label extension data (up to 2 years) continues to be presented at medical conferences, showing durable disease control and glucocorticoid dose reductions.

The Two-Sided Case

▲ Bull Case5
CRENESSITY is the first new treatment for classic CAH in 70 years, offering a steroid-sparing mechanism that directly addresses a large unmet need.
Sales are ramping rapidly: $301M in 2025, $153M Q1 2026, $184M Q2 2026, $211M Q3 2026, with the prescriber base nearly tripling year-over-year.
The drug enjoys ~80% reimbursement rates and high patient persistency, suggesting durable revenue growth.
Analyst consensus is strongly bullish (32 Buy/Strong Buy vs 5 Hold, 0 Sell) with a mean price target of $206 (41.9% upside from $145), and multiple top-tier firms (Evercore, Canaccord, HC Wainwright) have strong accuracy track records on NBIX.
IP protection extends to the early 2040s, providing a long commercial runway.
▼ Bear Case4
CRENESSITY captured ~10% of its target patient population in its first year ($301M in 2025), and further penetration may slow as the easy-to-reach patients are already on therapy.
The CAH market is small (estimated ~$500M-$700M total), limiting CRENESSITY's long-term peak sales ceiling even if it becomes standard of care.
Several large institutional holders (Wellington, Millennium, D.E. Shaw) significantly trimmed or nearly exited NBIX positions in Q2 2026, suggesting some smart money sees limited upside.
Insider sales via 10b5-1 plans by the CFO and other executives in September 2026 add a cautionary signal.

Upcoming Catalysts

  • Quarterly sales reports and commercial execution metrics (next: Q4 2026 / full-year 2026 results, likely early February 2027)
  • Potential European Medicines Agency (EMA) submission and approval decision for the EU market
  • Long-term safety and efficacy data presentations at medical conferences (e.g., ENDO, pediatric endocrinology meetings)
  • Any label expansion studies or data for younger pediatric patients (under age 4)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report

Sources · 9

Hover a chip for the title
1 fda.gov2 prnewswire.com3 prnewswire.com4 en.wikipedia.org5 accessdata.fda.gov6 crenessityhcp.com7 neurocrine.com8 varese-group.com9 mordorintelligence.com